Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tonix Medicines Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner and 1 distinct art unit. The company current prosecution activity is focused on this one specific administrative channel, suggesting a focused development or filing strategy within the pharmaceutical sector.
ROSSI, JULIA ANNE LORRAIN is the busiest examiner, overseeing 1 pending office action. With 1 distinct examiner and 1 distinct art unit, the company immediate patent goals are concentrated on the review of this single application. This structure means that the outcome of this specific office action will determine the immediate progress of the company biotechnological intellectual property. The presence of 1 pending office action indicates a streamlined prosecution phase where resources are directed toward a single technical disclosure. Practitioners must address the specific requirements of this art unit to advance the application.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROSSI, JULIA ANNE LORRAIN | 1 | 45.7% | +61.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18797812 | METHODS OF TREATING MIGRAINE | ROSSI, JULIA ANNE LORRAIN | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18797812 | METHODS OF TREATING MIGRAINE | ROSSI, JULIA ANNE LORRAIN | 1615 | §103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTonix Medicines Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Julia Anne Lorrain Rossi has the most, with 1 of Tonix Medicines Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
